2003 APR 3 - (NewsRx.com & NewsRx.net) -- Biopure Corp. (BPUR) announced that it has signed a cooperative research and development agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC) that will enable the NMRC to participate in a pivotal clinical trial of the company's investigational oxygen therapeutic Hemopure [hemoglobin glutamer - 250 (bovine), or HBOC-201] in prehospital trauma.
Participation in this collaborative effort is estimated to cost the NMRC at least $4 million.
Biopure will contribute an estimated $8.7 million, of which at least $643,000 will be provided during the first year.
The funding is intended to support a …
No comments:
Post a Comment